Búsqueda

IDIOMA/LANGUAGE

Bandera inglesa Bandera espanola

Publicaciones

  • CONGRESO
ISPOR

Martínez-Sesmero JM, Burgos R, Jornet S, Santiago A, Navarro H, Gorgas Q, Jolonch P, Díaz Moreno V, Griffa L, Oyagüez I

Economic evaluation of a patient support programme Abbvie Care 2.0 Immunology

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

ISPOR

Peral C, Gomez I, Burgos R , Rebollo F

Economic evaluations of etanercept in patients with psoriasis and psoriatic arthritis in Spain: a systematic review

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

ISPOR

Sabater E, Puente J, Oyagüez I, García-Campelo R, Reguart N, Rodriguez D, Cobo M, Moran M, Soto J

Cost-effectiveness of sequential treatment containing crizotinib for non small cell lung cancer (ALK+) patients

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

ISPOR

Mareque M, Oyagüez I, Morano R, Casado MA

Systematic review of herpes zoster epidemiology: available evidence in Spain related to specific sub-populations

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

ISPOR

Mareque M, Mingot E, López MF, Álvarez MT, García JP, Oyagüez I

Bypassing agents prophylaxis in patients with haemophilia and inhibitors undergoing surgery: a decision analysis in Spain 

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

ISPOR

Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A

Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia

20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

International Society of Pharmacoeconomics and Outcomes Research

González Flores E, Vera García R, Sabater Cabrera E, Tirado Mercier E, Granell Villalon M

Budget Impact analysis of regorafenib for the treatment in third and fourth lines of metastasic colorectal cancer in Spain

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

International Society of Pharmacoeconomics and Outcomes Research

de Andrés-Nogales F, Álvarez M, de Miquel MÁ, Segura T, Gil A, Cardona P, Casado MÁ, Nogueira RG, Dávalos A

Cost-effectiveness of mechanical thrombectomy using stent-retriever after intravenous t-PA compared with intravenous t-PA alone in the treatment of acute ischemic stroke due to large vessel occlusion in Spain

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

International Society of Pharmacoeconomics and Outcomes Research

de Andrés-Nogales F, Oyagüez I, Echave M, Arias L, Cervera E, Armadá F, Martínez C

Budget impact analysis of dexamethasone intravitreal implant for treatment of diabetic macular oedema in Spain

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

International Society of Pharmacoeconomics and Outcomes Research

Ortega-Joaquin N, Echave M, Oyagüez I, Garrido P, Felip E, Trigo J, Filori M, González P

Cost-analysis for toxicity management in advanced squamous non-small cell lung cancer: nivolumab vs docetaxel

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

International Society of Pharmacoeconomics and Outcomes Research

Echave M, Oyagüez I, Soria A, de la Cruz-Merino L, Arance A, Carrasco M, González P

Cost-utility analysis of nivolumab monotherapy for metastatic melanoma treatment

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

International Society of Pharmacoeconomics and Outcomes Research

González P, Felip E, Garrido, P, Trigo J, Ortega-Joaquin N, Echave M, Jimenez S, Oyagüez I

Cost-effectiveness analysis of nivolumab for the treatment of second-line advanced squamous non-small cell lung cancer (NSCLC) in Spain

19th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena, Austria. 29 oct- 2 nov 2016

Comunicaciones ISPOR

Vanaclocha F, Carrascosa JM, Caloto T, Elías I, Echave M, Tencer T

Budget impact analysis of apremilast on moderate to severe psoriasis in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Gonzalez C, Almodóvar R, Caloto T, Echave M, Elías I, Tencer T

Cost-utility of aprelimast for the treatment of psoriatic arthritis patients in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Carrascosa JM, Vanaclocha F, Caloto T, Echave M, Oyagüez I, Tencer T

Cost-utility analysis of apremilast for the treatment of moderate to severe psoriasis in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Almodóvar R, Gonzalez C, Caloto T, Elías I, Oyagüez I, Tencer T

Budget impact analysis of apremilast in patients with psoriatic arthritis in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Echave M, Ojanguren ME, Elías I, De Andrés-Nogales F, Oyagüez I, Casado MÁ, Crespo C

Cost-effectiveness of tiotropium in the treatment of patients with asthma.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Echave M, Oyagüez I, Lamas MJ, Rubio M, Subirá R

Aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer: cost-effectiveness based on VELOUR Best Efficacy Subgroup post-hoc analysis.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Rodríguez-González Moro JM, Menendez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F

Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged 50+ years in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Torres C, Oyagüez I, Prieto L, Rodriguez G, Nieto E, Levitch R, Aguilar A, Esteban J

Costs analysis of PCR Unvyero TM i60-ITI technique for detecting microorganisms in patients with suspected chronic infection at musculoskeletal implants.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Ortega-Joaquin N, Elías I, de la Cueva P, Del Pozo LJ, Boada A, Moreno D, Aguilar M, Mosquera E, Mirada A, Gibbons C, Oyagüez I

Cost-effectiveness of ingenol mebutate versus imiquimod 5% for actinic keratosis treatment in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Elias I, Ortega-Joaquin N, Aguilar M, Moreno D, Boada A, Del Pozo LJ, De la Cueva P, Mirada A, Mosquera E, Gibbons C, Oyagüez I

Cost-utility analysis of ingenol mebutate versus diclofenac 3% for actinic keratosis treatment in Spain.

18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.

Comunicaciones ISPOR

Solé A, Poveda JL, Girón R, Prados C, De Gracia J, Casado MA

Economic Impact linked to the reduction of exacerbations when a treatment regime with inhaled antibiotics is switched to aztreonam lysine in patients with cystic fibrosis and chronic pulmonary infection caused by Pseudomonas aeruginosa.

17th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Amsterdam, Holland. 8-12 nov 2014.

Comunicaciones ISPOR

Gros B, Soto J, Casado MA

Future costs inclusion in published economic evaluations: What is the current situation?

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Torres C, Betoret I, Sabater E, Riera M, Casado MA, Figueras M

Cost-effectiveness analysis of glycopyrronium bromide in the treatment of chronic obstructive pulmonary disease in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Álvarez-Sabín J, Masjuan J, Casado MA, Mar J, Oliva J, González-Rojas N

Costs in patients along first year poststroke in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Álvarez-Sabín J, Masjuan J, Yébenes M, Mar J, Oliva J, González-Rojas N

Disease burden of ischemic stroke along first year post-stroke in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Álvarez-Sabín J, Masjuan J, Torres C, Mar J, Oliva J, González-Rojas N

Health-related quality of life in patients along first year poststroke in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Morote J, Cozar JM, Durán I, Gómez F, León L, Maroto P, Miñana B, Solsona E, Oyagüez I, Casado MA, Roldán C, Gutierrez L, Hechmati G

Cost assessment of metastatic and non-metastatic castration-resistante prostate cancer patient-management in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Ariza-Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K

Cost-minimization analysis of subctuaneous abatacept in the treatment of rheumatoid arthritis in Spain.

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Menéndez R, Rodríguez-GonzálezMoro JM, Gros B, Echave M, Oyagüez I, Lwoff N, Egea-García M, Guijarro P

Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged ≥50 years in Spain: Preliminary results. 

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

Villarrubia R, Oyagüez I, Álvarez MT, Mingot ME, Parra R, Casado MA

Cost analysis of bypassing agent prophylaxis treatment versus on-demand therapy in hemophilia a with inhibitor in Spain. 

16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.

Comunicaciones ISPOR

De Andrés F, Vivancos J, Barriga FJ, Díaz F, Izquierdo L, Ortega MA, Castillo L, Ximénez-Carrillo A, Gómez-Escalonilla CI, Torres C, de Salas-Cansado M, Casado MA, Soto J, Gil-Nuñez A

Healthcare resource utilization and costs of cardioembolic stroke in the region of Madrid, Spain: preliminary results of CODICE study.

15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012.

Comunicaciones ISPOR

Sánchez-de la Rosa R, Sabater E, Casado MA

Cost analysis of glatiramer acetate versus fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.

15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012.

Comunicaciones ISPOR

Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I.

The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemia.

15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012.

Comunicaciones ISPOR

Cobo M, De Castro J, Isla D, Lozano V, Oyagüez I, Castro-Gomez AJ

Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy.

15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012.

Comunicaciones ISPOR

Martinez-Raga J, Casado MA, González Saiz F, Oñate J

Budgetary impact analysis of Buprenorphine/Naloxone (Suboxone®) in opioid maintenance treatment in Spain.

14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011.

Comunicaciones ISPOR

Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R

Cost-effectiveness Analysis of Disease Modifiying Drugs (Interferons and Glatiramer Acetate) as first line treatments in Remitting-Relapsing Multiple Sclerosis patients.

14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011.

Comunicaciones ISPOR

Sánchez-de la Rosa R, Sabater E, Casado MA

Budget impact analysis of first-line treatment for relapsing-remitting multiple sclerosis in Spain.

14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011.

Comunicaciones ISPOR

Garcia-Jurado L , Morano R, Torné A, Malvar A, Bayas JM, Pérez-Escolano I, Casado MA

Cost-efectiveness analysis of cervical cancer vaccination strategies in Spain.

14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

Comunicaciones ISPOR

Álvarez-Sabín J, Masjuan, J, Yébenes M, Mar J, Oliva J, González-Rojas N, Becerra V, Casado MA, CONOCES Study Investigators

Are hospital costs for stroke underestimated in Spain?
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011.

Comunicaciones ISPOR

Fernández-Rivera C, Torre-Cisneros J, Guirado-Perich L, Oyagüez I, Ruiz-Beato E

Cost-effectiveness modelto evaluate 200-day vs 100-day treatment with valganciclovir prophylaxis to reduce cytomegalovirus disease in high-risk (D+/R-) kidney transplant recipient in Spain.

14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011.

Comunicaciones ISPOR

Collar JM

Different comparators for the same new drug?

13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.

Comunicaciones ISPOR

Collar JM

The Joint Committee for New Drugs Evaluation in Spain: six years of experience.

13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.

Comunicaciones ISPOR

Román A, Barberá JA, Escribano P, Sala ML, Febrer L, Casado MA

Economic evaluation of iloprost, epoprostenol and treprostinil for the treatment of pulmonary arterial hypertension.

13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.

Comunicaciones ISPOR

Martinez-Moragon E, Palop M, de Diego A, Serra J, Caloto T, Nocea G, Sabater E

Factors affecting quality of life (QOL) of asthmatic patients in Spain.

13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.

Comunicaciones ISPOR

Picazo J, Mendez C, Oyagüez I, Casado MA, Guijarro PA

Cost-utility analysis of new pneumococcal conjugate vaccines in the regional immunization program of the Autonomous Region of Madrid - Impact on invasive pneumococcal disease.

13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.

Comunicaciones ISPOR

Sanchez-Carazo JL, Dauden E, Vanaclocha F, Toribio J, Pujol R Puig Ll, Yébenes M, Sabater FJ

Cost of moderate to severe psoriasis patients in Spain.

12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Dauden E, Gratacos J, Moreno JC, Gómez-Reino J, Rodríguez V, Sabater FJ, Casado MA

Health-related quality of life in patients with psoriatic arthritis.

12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Dauden E, Gratacos J, Moreno JC, Gómez-Reino J, Rodríguez V, Sabater FJ, Casado MA

A cost-of-illness study of psoriatic arthritis in Spain.

12th Annual European Congress European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Puente J, Calderero V, García-Muro X, Trigo JM, Castro AJ, Martín-Escudero V, Yébenes M, Casado MA

Cost of managing adverse events in the treatment of first line metastasic renal cell carcinoma: bevacizumab + interferon alpha-2a compared with sunitinib in Spain.

12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Marinello J, March JR, Blanes JI, Martínez-Aguilar E, Escudero JR, Masegosa A, Lizano C, Massó JM, Yébenes M, Casado MA

Cost of an episode of diabetic foot ulcer in Spain.

12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Cortés J, Seguí MA, Frias C, Betegón L, Oyagüez I, Casado MA

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer progressed after anthracycline chemotherapy in Spain.

12th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009.

Comunicaciones ISPOR

Collar JM, Porta-Etessam J, Tobaruela JL, Rabes C, Casado MA

Burden of disease in moderate Alzheimer disease patients with depression in Spain (Ideal Study).

11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008.

 

Comunicaciones ISPOR

Buti M, Brosa M, Casado MA, Rueda M, Esteban R

Modeling the long-term cost-effectiveness of chronic hepatitis B therapies in Spain.

11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008.

Comunicaciones ISPOR

Puig Ll, Sanchez-Carazo JL, Dauden E, Vanaclocha F, Toribio J, Pujol R, Casado MA, Sabater FJ

Quality of life in moderate to severe psoriasis patients in Spain.

11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008.